Literature DB >> 20220122

Comparative analysis of brain structure, metabolism, and cognition in myotonic dystrophy 1 and 2.

Y G Weber1, R Roebling, J Kassubek, S Hoffmann, A Rosenbohm, M Wolf, P Steinbach, K Jurkat-Rott, H Walter, S N Reske, F Lehmann-Horn, F M Mottaghy, H Lerche.   

Abstract

OBJECTIVE: Myotonic dystrophy type 1 and 2 (DM1/DM2) are multisystemic diseases with common cognitive deficits beside the cardinal muscular symptoms. We performed a comprehensive analysis of cerebral abnormalities to compare the neuropsychological defects with findings in different imaging methods in the same cohort of patients.
METHODS: Neuropsychological investigations, structural cerebral MRI including brain parenchymal fraction (BPF) and voxel-based morphometry (VBM), and (18)F-deoxy-glucose PET (FDG-PET) were performed in patients (20 DM1 and 9 DM2) and matched healthy controls, and analyzed using statistical parametric mapping (SPM2).
RESULTS: DM1 and DM2 patients showed typical neuropsychological deficits with a pronounced impairment of nonverbal episodic memory. Both patient groups showed a reduction of the global gray matter (measured by BPF), which could be localized to the frontal and parietal lobes by VBM. Interestingly, VBM revealed a bilateral hippocampal volume reduction that was correlated specifically to both a clinical score and episodic memory deficits. VBM also revealed a pronounced change of thalamic gray matter. White matter lesions were found in >50% of patients and their extent was correlated to psychomotor speed. FDG-PET revealed a frontotemporal hypometabolism, independent of the decrease in cortical gray matter. All abnormalities were similar in both patient groups but more pronounced for DM1.
CONCLUSIONS: Our results suggest that 1) some of the characteristic cognitive deficits of these patients are linked to specific structural cerebral changes, 2) decreases in gray matter and metabolism are independent processes, and 3) the widespread brain abnormalities are more pronounced in DM1.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20220122     DOI: 10.1212/WNL.0b013e3181d8c35f

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  47 in total

1.  Cerebral and muscle MRI abnormalities in myotonic dystrophy.

Authors:  Daniel T Franc; Ryan L Muetzel; Paul R Robinson; Craig P Rodriguez; Joline C Dalton; Cameron E Naughton; Bryon A Mueller; Jeffrey R Wozniak; Kelvin O Lim; John W Day
Journal:  Neuromuscul Disord       Date:  2012-01-30       Impact factor: 4.296

Review 2.  Therapeutics development in myotonic dystrophy type 1.

Authors:  Erin Pennock Foff; Mani S Mahadevan
Journal:  Muscle Nerve       Date:  2011-05-23       Impact factor: 3.217

Review 3.  Myotonic dystrophy mouse models: towards rational therapy development.

Authors:  Mário Gomes-Pereira; Thomas A Cooper; Geneviève Gourdon
Journal:  Trends Mol Med       Date:  2011-07-02       Impact factor: 11.951

4.  Brain MRI abnormalities in the adult form of myotonic dystrophy type 1: A longitudinal case series study.

Authors:  Renata Conforti; Mario de Cristofaro; Adriana Cristofano; Barbara Brogna; Angela Sardaro; Gioacchino Tedeschi; Sossio Cirillo; Alfonso Di Costanzo
Journal:  Neuroradiol J       Date:  2016-01-11

Review 5.  Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects.

Authors:  Giovanni Meola; Rosanna Cardani
Journal:  Neurol Sci       Date:  2017-01-11       Impact factor: 3.307

6.  Tractography reveals diffuse white matter abnormalities in Myotonic Dystrophy Type 1.

Authors:  Jeffrey R Wozniak; Bryon A Mueller; Kelvin O Lim; Laura S Hemmy; John W Day
Journal:  J Neurol Sci       Date:  2014-04-13       Impact factor: 3.181

7.  Frontostriatal dysexecutive syndrome: a core cognitive feature of myotonic dystrophy type 2.

Authors:  Stojan Peric; Gorana Mandic-Stojmenovic; Elka Stefanova; Dusanka Savic-Pavicevic; Jovan Pesovic; Vera Ilic; Valerija Dobricic; Ivana Basta; Dragana Lavrnic; Vidosava Rakocevic-Stojanovic
Journal:  J Neurol       Date:  2014-10-28       Impact factor: 4.849

8.  Clusters of cognitive impairment among different phenotypes of myotonic dystrophy type 1 and type 2.

Authors:  Stojan Peric; Vidosava Rakocevic Stojanovic; Gorana Mandic Stojmenovic; Vera Ilic; Masa Kovacevic; Aleksandra Parojcic; Jovan Pesovic; Milija Mijajlovic; Dusanka Savic-Pavicevic; Giovanni Meola
Journal:  Neurol Sci       Date:  2016-11-28       Impact factor: 3.307

Review 9.  Antisense oligonucleotides: rising stars in eliminating RNA toxicity in myotonic dystrophy.

Authors:  Zhihua Gao; Thomas A Cooper
Journal:  Hum Gene Ther       Date:  2013-01-30       Impact factor: 5.695

10.  Muscleblind-like 2-mediated alternative splicing in the developing brain and dysregulation in myotonic dystrophy.

Authors:  Konstantinos Charizanis; Kuang-Yung Lee; Ranjan Batra; Marianne Goodwin; Chaolin Zhang; Yuan Yuan; Lily Shiue; Melissa Cline; Marina M Scotti; Guangbin Xia; Ashok Kumar; Tetsuo Ashizawa; H Brent Clark; Takashi Kimura; Masanori P Takahashi; Harutoshi Fujimura; Kenji Jinnai; Hiroo Yoshikawa; Mário Gomes-Pereira; Geneviève Gourdon; Noriaki Sakai; Seiji Nishino; Thomas C Foster; Manuel Ares; Robert B Darnell; Maurice S Swanson
Journal:  Neuron       Date:  2012-08-09       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.